JP2005525798A - 微生物内での組み換えタンパク質の生産方法 - Google Patents

微生物内での組み換えタンパク質の生産方法 Download PDF

Info

Publication number
JP2005525798A
JP2005525798A JP2003566193A JP2003566193A JP2005525798A JP 2005525798 A JP2005525798 A JP 2005525798A JP 2003566193 A JP2003566193 A JP 2003566193A JP 2003566193 A JP2003566193 A JP 2003566193A JP 2005525798 A JP2005525798 A JP 2005525798A
Authority
JP
Japan
Prior art keywords
plasminogen
seq
nucleic acid
plasmin
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003566193A
Other languages
English (en)
Japanese (ja)
Inventor
ルディ・スシロ
ハンス・クリスチャン・コルティンク
ハンス・ギュンテル・ガッセン
マルティン・ヒルス
ラルフ・パステルナック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trommsdorff GmbH and Co KG
Original Assignee
Trommsdorff GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trommsdorff GmbH and Co KG filed Critical Trommsdorff GmbH and Co KG
Publication of JP2005525798A publication Critical patent/JP2005525798A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
JP2003566193A 2002-02-06 2003-02-06 微生物内での組み換えタンパク質の生産方法 Pending JP2005525798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02002716 2002-02-06
US35780902P 2002-02-21 2002-02-21
PCT/DE2003/000341 WO2003066842A2 (de) 2002-02-06 2003-02-06 Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen

Publications (1)

Publication Number Publication Date
JP2005525798A true JP2005525798A (ja) 2005-09-02

Family

ID=36743321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003566193A Pending JP2005525798A (ja) 2002-02-06 2003-02-06 微生物内での組み換えタンパク質の生産方法

Country Status (7)

Country Link
EP (1) EP1472346A2 (de)
JP (1) JP2005525798A (de)
CN (1) CN1768138A (de)
AU (1) AU2003210137A1 (de)
CA (1) CA2475277A1 (de)
MX (1) MXPA04007585A (de)
WO (1) WO2003066842A2 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509181A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルアミノペプチダーゼ活性を欠くピチア・パストリスにおける治療用タンパク質の製造方法
JP2019500425A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 肝組織損傷及びその関連疾患を予防及び治療するための方法
JP2019500426A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
JP2020502155A (ja) * 2016-12-15 2020-01-23 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 心臓病変を改善するための方法
US10874721B2 (en) 2015-12-18 2020-12-29 Talengen International Limited Method for preventing and treating cervical erosion
US11007253B2 (en) 2015-12-18 2021-05-18 Talengen International Limited Method for preventing or treating radiation and chemical damage
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563100B (zh) * 2006-08-28 2013-08-07 李季男 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
EP2056865B1 (de) 2006-08-28 2013-12-25 Omnio Healer AB Neues arzneimitteltarget zur verhinderung und behandlung von parodontalerkrankungen, verbesserung der heilung von parodontalwunden und förderung der mundgesundheit
CN102482338B (zh) 2009-07-10 2016-09-28 斯路姆基因公司 纤溶酶原和纤溶酶的变体
KR20140015289A (ko) 2011-01-05 2014-02-06 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민 변이체
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
DK3391902T3 (da) 2015-12-18 2023-11-20 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
EP3395359B1 (de) * 2015-12-18 2023-11-01 Talengen International Limited Plasminogen zur verhinderung oder behandlung von akuter und chronischer thrombose
CN106890323A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
CN106890319A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
CN108210902A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪肝的药物及其用途
CN108210911A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 一种促进胰岛素分泌的方法
CN108210915A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 改善心脏病变的药物及其用途
JP7313058B2 (ja) 2016-12-15 2023-07-24 タレンゲン インターナショナル リミテッド 組織器官の繊維化を予防及び治療するための方法
CN110366427A (zh) * 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防和治疗病理性肾组织损伤的方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
CN109971736B (zh) * 2017-12-27 2021-07-23 中科院大连化物所盘锦产业技术研究院有限公司 与草莓软化相关的氨基己糖苷酶及编码基因、制备与应用
CN110358780A (zh) * 2018-04-10 2019-10-22 东莞泛亚太生物科技有限公司 一种编码β-甘露聚糖酶的基因，以及含该基因的重组质粒和重组菌及其构建方法
CN109456989B (zh) * 2018-10-31 2022-03-29 陕西慧康生物科技有限责任公司 一种提高毕赤酵母分泌表达的载体的构建方法
CN116854792A (zh) * 2023-04-28 2023-10-10 优睿赛思(武汉)生物科技有限公司 突变型α-factor信号肽及其编码基因、表达载体和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
JP4047170B2 (ja) * 2000-12-21 2008-02-13 トロム−イクス・ナムローゼ・フエンノートシャップ 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509181A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルアミノペプチダーゼ活性を欠くピチア・パストリスにおける治療用タンパク質の製造方法
JP7117012B2 (ja) 2015-12-18 2022-08-12 タレンゲン インターナショナル リミテッド 糖尿病網膜症を予防または治療するための方法
JP2019500425A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 肝組織損傷及びその関連疾患を予防及び治療するための方法
JP2019500426A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
JP2020059730A (ja) * 2015-12-18 2020-04-16 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
US10874721B2 (en) 2015-12-18 2020-12-29 Talengen International Limited Method for preventing and treating cervical erosion
US11007253B2 (en) 2015-12-18 2021-05-18 Talengen International Limited Method for preventing or treating radiation and chemical damage
JP2020502155A (ja) * 2016-12-15 2020-01-23 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 心臓病変を改善するための方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11311607B2 (en) 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver
JP7194440B2 (ja) 2016-12-15 2022-12-22 タレンゲン インターナショナル リミテッド 心臓病変を改善するための方法
US11547746B2 (en) 2016-12-15 2023-01-10 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof

Also Published As

Publication number Publication date
WO2003066842A2 (de) 2003-08-14
AU2003210137A8 (en) 2003-09-02
MXPA04007585A (es) 2005-09-20
WO2003066842A3 (de) 2004-06-10
CN1768138A (zh) 2006-05-03
AU2003210137A1 (en) 2003-09-02
CA2475277A1 (en) 2003-08-14
EP1472346A2 (de) 2004-11-03

Similar Documents

Publication Publication Date Title
JP2005525798A (ja) 微生物内での組み換えタンパク質の生産方法
RU2604810C2 (ru) Варианты плазминогена и плазмина
RU2604807C2 (ru) Варианты плазминогена и плазмина
RU2564131C2 (ru) Варианты плазминогена и плазмина
US20050124036A1 (en) Method for producing recombinant proteins in micro-organisms
US20080058256A1 (en) Methods for the treatment of thrombosis
JP2007195558A (ja) 活性化されたミクロプラスミンの産生方法
JPH0824579B2 (ja) ヒトウロキナーゼ
Yu et al. Expression and purification of ancrod, an anticoagulant drug, in Pichia pastoris
DK175369B1 (da) Anvendelse af tPA-varianter til fremstilling af et terapeutisk præparat til behandling af vaskulæresygdomme
JPH08231595A (ja) 繊維素溶解性のトロンビン阻害性質を有するキメラたん白質
RU2247777C2 (ru) Модифицированный активатор плазминогена урокиназного типа, последовательность днк, рекомбинантная плазмида, штамм-продуцент, способ получения модифицированного активатора плазминогена урокиназного типа и фармацевтическая композиция, обладающая тромболитическим действием
CN108473542B (zh) 遗传修饰的酵母细胞和改进的用于生产凝块特异性链激酶的方法
JPH08231594A (ja) 繊維素溶解性の血液凝固阻害性質を有するたん白質
US5908625A (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
JP2000504941A (ja) トロンビンによって活性化され得るプラスミノーゲンアクチベーター
AU2014228858A1 (en) Dual reactivity potent Kunitz inhibitor of fibrinolysis
WO1996017928A1 (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
JP2005278550A (ja) ２本鎖組織プラスミノーゲンアクチベーターの製造法
NZ622210B2 (en) Plasminogen and plasmin variants
MXPA99000966A (en) Plasminogen activator capable of being activated by thrombin
NZ530114A (en) Fibrinolytically active polypeptide

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090113